Summary auto-generated
This study examined hepatitis C virus (HCV) genotypes in Egyptian patients and their association with neu-oncoprotein overexpression and hepatocellular carcinoma (HCC) development. Researchers analyzed serum samples from 27 asymptomatic carriers, 29 chronic active hepatitis patients, and 33 HCC patients, all confirmed HCV-positive by EIA, immunoblotting, and RT-PCR. HCV genotyping revealed that 84.3% carried single genotypes: genotype 4 (57.3%), type 1a (12.4%), type 2a (11.2%), type 1b (2.2%), and type 10a (1.2%), with 15.7% showing mixed infections. Genotype 4 predominated in chronic liver disease (68.9% in chronic hepatitis, 69.7% in HCC) versus asymptomatic carriers (29.6%). Neu-oncoprotein levels were significantly elevated in chronic hepatitis and HCC patients compared to controls and asymptomatic carriers. Importantly, genotypes 4 and 1b showed strong association with neu-oncoprotein overexpression across all patient groups. These findings suggest genotypes 4 and 1b represent risk factors for neu-oncoprotein overexpression and progressive liver disease leading to HCC development.
Key findings
- HCV genotype 4 was the predominant subtype in Egyptian patients with chronic liver disease (57.3% overall), particularly in CAH and HCC patients, but not in asymptomatic carriers
- Genotypes 4 and 1b showed significant association with neu-oncoprotein overexpression, which was elevated in 79% of HCC and 65% of CAH patients
- Mixed HCV infection occurred in 15.7% of patients, with genotype 4 present in 13 of 14 cases, much higher than European and USA rates
- Neu-oncoprotein overexpression was significantly associated with more aggressive liver disease progression, suggesting genotypes 4 and 1b may induce enhanced viral pathogenesis
This summary was generated automatically from the article PDF and is not part of the original publication. Refer to the PDF for the authoritative text.
Abstract
The distribution of hepatitis C virus (HCV) genotypes among Egyptian patients positive for anti-HCV was determined and their influence, when combined with neu-oncoprotein overexpression, on the development of hepatocellular carcinoma (HCC) was examined. The study groups included asymptomatic carriers (ASC) and patients with chronic active hepatitis (CAH) and HCC. HCV genomes were detected in the sera of 27 ASC, 29 CAH and 33 HCC patients known to have HCV infection defined by EIA and recombinant immunoblotting techniques (Inno-LiA) as well as by reverse transcriptase (RT)-PCR. The HCV genotype was determined by a reverse hybridisation technique (Inno-LiPA I and II), whereas neu-overexpression was detected by the Oncogene Science EIA Kit. Eighty-nine patients were eligible for HCV genotyping; 75 patients (84.3%) were infected with a single genotype, including 1a in 11 patients (12.4%), 1b in 2 patients (2.2%) and 2a in 10 patients (11.2%). Genotype 4 (a or c+d) was detected in 51 patients (57.3%) and only one patient had genotype 10a (1.2%). Fourteen patients (15.7%) showed mixed infection; eight of them had 1a+4 (a or c+d) and four had 2a+4 (a or c+d); the remaining two cases had 1a+2a and 1b+2a. The results revealed an increased incidence of genotype 4 in CAH and HCC patients in comparison with ASC. There was also a significant overexpression of neu-oncoprotein in CAH and HCC patients compared with ASC, which was significantly associated with subtype 4 infection. The results suggest that infection with subtype 1a and 4 HCV may be considered a risk factor for the induction of neu-overexpression and subsequent development of HCC.